Leap Investments’s Puma Biotechnology PBYI Stock Holding History

Leap Investments’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-29,100	Closed	-$370K	–	465
2019 Q2	$370K	Buy	+29,100	New	+$670K	0.5%	66

Other funds holding PBYI

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Leap Investments's PBYI Position: Q3 2019 in Review

Leap Investments sold out of Puma Biotechnology (PBYI) in Q3 2019, closing a stake of 29,100 shares — an estimated $370K sold.

Leap Investments first reported a position in PBYI in Q2 2019 and held it in 1 quarter. The position peaked at $370K in Q2 2019. 144 funds tracked by Wall St. Rank hold PBYI as of Q3 2019.

Leap Investments reported no remaining Puma Biotechnology position as of Q3 2019 after selling out during the quarter.
Leap Investments sold 29,100 Puma Biotechnology shares in Q3 2019, an estimated $370K.
Leap Investments first reported a position in Puma Biotechnology in Q2 2019 and held it in 1 quarter.
Leap Investments's Puma Biotechnology position peaked at $370K in Q2 2019.
144 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2019.

Based on Leap Investments's 13F filing for Q3 2019, filed 13 Nov 2019.